Sign in to view content

Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy

Judy E. Kim, MD, FASRS
Chirag D. Jhaveri, MD, FASRS
Michael S. Ip, MD
Arshad M. Khanani, MD, MA, FASRS
Jordana G Fein, MD, MS
Dennis M. Marcus, MD
Diana V Do, MD, FASRS

Video
Published 2024

Related

Intraocular Pressure Elevation Immediately Following High-Volume (0.07 mL-0.15 mL) vs Standard Volume (0.05 mL) Injections
Scott D Walter, MD, MSc, FASRS
Annual Meeting Talks
2024
Protocol T Extension Results
John A. Wells, MD, FACS
Updates from the Field
2019
Agitation of the Syringe as a Cause of Inflammation After Intravitreal Injection of Aflibercept: A Randomized, Double-blind, Controlled Clinical Trial
Gustavo Barreto de Melo, MD, PhD, FASRS
Annual Meeting Talks
2020

Category: Diabetic Retinopathy

See more